Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Christopher J. Sweeney(The University of Adelaide), Robert S. DiPaola(University of Kentucky), David F. Jarrard(University of Wisconsin System), Mario A. Eisenberger(Johns Hopkins University), Manish Kohli(Mayo Clinic in Arizona), Daniel H. Shevrin(NorthShore University HealthSystem), Glenn Liu(University of Wisconsin Carbone Cancer Center), Joel Picus(Washington University in St. Louis), Maha Hussain(Northwestern University), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Yu‐Hui Chen(Dana-Farber Cancer Institute), Robert Dreicer(University of Virginia), Jorge A. García(Cleveland Clinic), Matthew M. Cooney(University Hospitals Cleveland Medical Center), Noah M. Hahn(Johns Hopkins University), Yu-Ning Wong(Fox Chase Cancer Center), Michael A. Carducci(Sidney Kimmel Comprehensive Cancer Center)
New England Journal of Medicine
August 5, 2015
10.1056/nejmoa1503747
Cited by 2,825

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k